

VentriPoint Appoints Mary-Pierre Waiss Vice President of Clinical Development

SEATTLE, July 1, 2008 – VentriPoint Diagnostics (TSX: VPT) today announced that it has appointed Mary-Pierre Waiss vice president of clinical development for VentriPoint Inc., its wholly owned operating subsidiary.

Waiss brings 25 years of experience in the field of cardiac imaging to VentriPoint. She was most recently a research scientist in the Cardiovascular Research Lab at the University of Washington. In this capacity, she collected and analyzed data, as well as evaluated and developed protocols related to the anatomy, function and volume calculations of the right ventricle.

“Mary-Pierre’s experience in cardiac imaging will be beneficial as we continue the development of the VentriPoint Diagnostic System,” said Joseph Ashley, president and CEO of VentriPoint Diagnostics. “We especially look forward to her contributions in the collection and analysis of data as we finalize additional databases in anticipation of commercial sales in early 2009.”

Waiss previously held positions at Children’s Hospital of Boston, Seattle Children’s Hospital & Regional Medical Center and Group Health Cooperative.

Waiss received her bachelor’s degree in Diagnostic Ultrasound from Seattle University and is registered by the ARDMS with specialty in adult and pediatric echocardiography. She is a member of the American Society of Echocardiography, the American Heart Association and the Western Washington Society of Echo.

About VentriPoint Diagnostics

VentriPoint Diagnostics, through its wholly owned subsidiary, VentriPoint Inc., creates diagnostic tools to monitor patients with heart disease – the number one

cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon technology received by VentriPoint through its technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer
VentriPoint Diagnostics Ltd.
Telephone: (206) 283-0221, ext. 402
Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.